167 related articles for article (PubMed ID: 31755385)
21. The plasminogen activator system and cancer.
McMahon B; Kwaan HC
Pathophysiol Haemost Thromb; 2008; 36(3-4):184-94. PubMed ID: 19176991
[TBL] [Abstract][Full Text] [Related]
22. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
[TBL] [Abstract][Full Text] [Related]
23. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
24. Endothelial cell proteases: physiological role and regulation.
Menashi S; Lu H; Soria C; Legrand Y
Baillieres Clin Haematol; 1993 Sep; 6(3):559-76. PubMed ID: 7517736
[TBL] [Abstract][Full Text] [Related]
25. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
26. Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces.
Anglés-Cano E
Chem Phys Lipids; 1994 Jan; 67-68():353-62. PubMed ID: 8187235
[TBL] [Abstract][Full Text] [Related]
27. Annexin II: a plasminogen-plasminogen activator co-receptor.
Kim J; Hajjar KA
Front Biosci; 2002 Feb; 7():d341-8. PubMed ID: 11815288
[TBL] [Abstract][Full Text] [Related]
28. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Illemann M; Bird N; Majeed A; Laerum OD; Lund LR; Danø K; Nielsen BS
Int J Cancer; 2009 Apr; 124(8):1860-70. PubMed ID: 19123477
[TBL] [Abstract][Full Text] [Related]
29. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Tang L; Han X
Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
[TBL] [Abstract][Full Text] [Related]
30. Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Beaufort N; Debela M; Creutzburg S; Kellermann J; Bode W; Schmitt M; Pidard D; Magdolen V
Biol Chem; 2006 Feb; 387(2):217-22. PubMed ID: 16497155
[TBL] [Abstract][Full Text] [Related]
31. [Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
Halámková J; Kiss I; Tomášek J; Pavlovský Z; Tuček S; Penka M
Vnitr Lek; 2012 Feb; 58(2):129-34. PubMed ID: 22463093
[TBL] [Abstract][Full Text] [Related]
32. Physiology and pathophysiology of the plasminogen system in the kidney.
Svenningsen P; Hinrichs GR; Zachar R; Ydegaard R; Jensen BL
Pflugers Arch; 2017 Nov; 469(11):1415-1423. PubMed ID: 28656379
[TBL] [Abstract][Full Text] [Related]
33. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
35. Urokinase Type Plasminogen Activator and the Molecular Mechanisms of its Regulation in Cancer.
Santibanez JF
Protein Pept Lett; 2017; 24(10):936-946. PubMed ID: 28820062
[TBL] [Abstract][Full Text] [Related]
36. Stimulation of tPA-dependent provisional extracellular fibrin matrix degradation by human recombinant soluble melanotransferrin.
Bertrand Y; Demeule M; Rivard GE; Béliveau R
Biochim Biophys Acta; 2006 Oct; 1763(10):1024-30. PubMed ID: 16979249
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Baker EA; Bergin FG; Leaper DJ
Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
[TBL] [Abstract][Full Text] [Related]
38. Pathophysiology of the plasminogen/plasmin system.
Lijnen HR
Int J Clin Lab Res; 1996; 26(1):1-6. PubMed ID: 8739849
[TBL] [Abstract][Full Text] [Related]
39. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer.
Mazar AP
Anticancer Drugs; 2001 Jun; 12(5):387-400. PubMed ID: 11395568
[TBL] [Abstract][Full Text] [Related]
40. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
